Quantum Biopharma (QNTM) Competitors $6.24 -0.06 (-0.95%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock QNTM vs. ONCY, VRCA, VNRX, PMVP, ICCC, STRO, PDSB, CUE, CTMX, and MDCXShould you be buying Quantum Biopharma stock or one of its competitors? The main competitors of Quantum Biopharma include Oncolytics Biotech (ONCY), Verrica Pharmaceuticals (VRCA), VolitionRx (VNRX), PMV Pharmaceuticals (PMVP), ImmuCell (ICCC), Sutro Biopharma (STRO), PDS Biotechnology (PDSB), Cue Biopharma (CUE), CytomX Therapeutics (CTMX), and Medicus Pharma (MDCX). These companies are all part of the "pharmaceutical products" industry. Quantum Biopharma vs. Oncolytics Biotech Verrica Pharmaceuticals VolitionRx PMV Pharmaceuticals ImmuCell Sutro Biopharma PDS Biotechnology Cue Biopharma CytomX Therapeutics Medicus Pharma Quantum Biopharma (NASDAQ:QNTM) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, community ranking, institutional ownership and earnings. Do analysts prefer QNTM or ONCY? Oncolytics Biotech has a consensus price target of $4.33, indicating a potential upside of 662.91%. Given Oncolytics Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Oncolytics Biotech is more favorable than Quantum Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quantum Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Oncolytics Biotech 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer QNTM or ONCY? In the previous week, Oncolytics Biotech had 1 more articles in the media than Quantum Biopharma. MarketBeat recorded 4 mentions for Oncolytics Biotech and 3 mentions for Quantum Biopharma. Quantum Biopharma's average media sentiment score of 0.82 beat Oncolytics Biotech's score of 0.31 indicating that Quantum Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quantum Biopharma 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oncolytics Biotech 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Is QNTM or ONCY more profitable? Quantum Biopharma's return on equity of -84.21% beat Oncolytics Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Quantum BiopharmaN/A -84.21% -62.63% Oncolytics Biotech N/A -141.15%-84.73% Do institutionals & insiders have more ownership in QNTM or ONCY? 1.2% of Quantum Biopharma shares are owned by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are owned by institutional investors. 8.5% of Quantum Biopharma shares are owned by company insiders. Comparatively, 0.1% of Oncolytics Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has preferable valuation and earnings, QNTM or ONCY? Oncolytics Biotech is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQuantum BiopharmaN/AN/A-$17.90M-$15.70-0.40Oncolytics BiotechN/AN/A-$20.56M-$0.30-1.89 Does the MarketBeat Community prefer QNTM or ONCY? Oncolytics Biotech received 160 more outperform votes than Quantum Biopharma when rated by MarketBeat users. CompanyUnderperformOutperformQuantum BiopharmaN/AN/AOncolytics BiotechOutperform Votes16068.67% Underperform Votes7331.33% Which has more risk & volatility, QNTM or ONCY? Quantum Biopharma has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500. Comparatively, Oncolytics Biotech has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. SummaryOncolytics Biotech beats Quantum Biopharma on 8 of the 14 factors compared between the two stocks. Remove Ads Get Quantum Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for QNTM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QNTM vs. The Competition Export to ExcelMetricQuantum BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.98M$6.25B$5.28B$7.36BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-0.406.6921.6317.68Price / SalesN/A222.70371.0892.88Price / CashN/A65.6738.1534.64Price / Book0.295.776.373.94Net Income-$17.90M$142.01M$3.20B$247.45M7 Day Performance-13.09%2.88%1.79%0.48%1 Month Performance27.61%-13.93%-9.41%-7.08%1 Year PerformanceN/A-12.36%9.61%-0.35% Quantum Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QNTMQuantum BiopharmaN/A$6.24-1.0%N/AN/A$11.98MN/A-0.40N/AGap DownONCYOncolytics Biotech2.0242 of 5 stars$0.59-5.3%$4.33+634.5%-46.0%$50.99MN/A-2.1930VRCAVerrica Pharmaceuticals3.7991 of 5 stars$0.55+14.2%$9.50+1,618.2%-92.9%$50.75M$7.57M-0.3040Short Interest ↑VNRXVolitionRx1.7467 of 5 stars$0.50+2.9%$3.33+563.7%-28.3%$50.60M$1.23M-1.3980Analyst ForecastGap DownPMVPPMV Pharmaceuticals3.0342 of 5 stars$0.95+9.2%$5.67+495.2%-36.4%$49.44MN/A-0.9550Positive NewsICCCImmuCell0.2144 of 5 stars$5.50+1.7%N/A+6.7%$49.41M$26.49M-11.0070High Trading VolumeSTROSutro Biopharma4.2821 of 5 stars$0.60-0.9%$6.63+1,009.9%-86.0%$49.22M$62.04M-0.37240Positive NewsGap DownPDSBPDS Biotechnology1.6847 of 5 stars$1.08+4.9%$9.00+733.3%-60.6%$49.03MN/A-0.9320Short Interest ↓CUECue Biopharma4.3275 of 5 stars$0.79+3.3%$3.00+279.3%-49.8%$48.90M$9.29M-0.8860News CoverageGap DownCTMXCytomX Therapeutics4.039 of 5 stars$0.61+13.8%$4.77+687.4%-67.9%$48.55M$138.10M3.57170Analyst ForecastNews CoverageMDCXMedicus PharmaN/A$3.61+0.8%$12.00+232.4%N/A$48.43MN/A0.00N/AAnalyst ForecastPositive NewsGap Up Remove Ads Related Companies and Tools Related Companies Oncolytics Biotech Alternatives Verrica Pharmaceuticals Alternatives VolitionRx Alternatives PMV Pharmaceuticals Alternatives ImmuCell Alternatives Sutro Biopharma Alternatives PDS Biotechnology Alternatives Cue Biopharma Alternatives CytomX Therapeutics Alternatives Medicus Pharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QNTM) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredIf Gold Is ‘Stalling,’ Why Are Banks Hoarding Billions In Secret?Prosperity was something every American family could build, protect, and pass down. Because that's what legacy...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quantum Biopharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quantum Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy QNTM Stock Free QNTM Stock Alerts